ArticleSAGE open medicine2026
Toward equitable transplant protocols: Thymoglobulin vs. Basiliximab in African-American kidney transplantation shows higher infection risk without survival benefit.
Article in SAGE open medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In kidney transplantation, induction therapy is often selected based on perceived immunologic risk for acute rejection, commonly considering African American (AA) ethnicity, panel reactive antibody (PRA) levels > 20%, and retransplantation. Aims: Compare post-transplant outcomes in African American kidney transplant recipients between two induction agents, rabbit anti-thymocyte globulin (rATG) and basiliximab and followed long-term. Methods: This single-center retrospective study included 173 AA KTRs followed for a mean of 39.7 ± 26.3 months. Patients received induction with either rATG (n = 71, 41%) or basiliximab (n = 102, 59%). All recipients were maintained on calcineurin inhibitor-based triple immunosuppression. Backward stepwise regression was used to obtain final adjusted models, and time to graft loss was analyzed using Cox proportional hazards regression (STATA 15). Results: There were no significant differences in overall graft survival (p = 0.75), or death censored graft survival (p=0.28), between the two induction groups. The incidence of first biopsy-proven acute rejection (BPAR) was similar (p = 0.14). Compared with basiliximab, rATG induction significantly increased the risk of viral infections (p = 0.019), bacterial infections (p = 0.025), and overall infections (p = 0.035). Infections were a risk factor for late graft loss (p = 0.039). Conclusion: Among AA kidney transplant recipients, the use of depleting induction therapy with rATG did not confer benefit for graft or patient survival in the intermediate and long-term but was associated with a significantly higher risk of post-transplant infections. These findings suggest that the use of depleting antibody induction should be carefully balanced against infection risk and that risk stratification based solely on ethnicity should be reconsidered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.